Oncorena is aiming to save human lives by transforming a natural substance into a breakthrough therapy treatment for advanced kidney cancer. We have completed all preclinical studies and are moving into early-stage clinical development. The objective is to confirm the powerful anti-tumor activity of our drug candidate - based on the natural substance orellanine - in advanced kidney cancer patients. Oncorena AB is headquartered in Lund, Sweden.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Scheelevägen 2, Lund,skane County 223 63,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- oncorena.com
- HQ
- Lund, Skane County
Oncorena Ab Questions
Oncorena Ab's website is oncorena.com
Oncorena Ab's LinkedIn profile is https://se.linkedin.com/company/oncorena-ab
Oncorena Ab has
9 employees.
View email and phone details for 9
employees at Oncorena Ab.
Oncorena Ab's industry is
Pharmaceutical Manufacturing
Oncorena Ab's top competitors are
Oncopeptides Ab (Publ),
Nanexa Ab,
Neogap Therapeutics Ab,
Kancera,
Hemab Therapeutics,
Pharmnovo,
Gesynta Pharma Ab,
Sortina Pharma,
Nwise Ab,
Novocure.
Oncorena Ab's categories are Pharmaceutical Manufacturing
Oncorena Ab's founding year is 2011
